Oral to iv phenobarbital conversion

These drugs may decrease growth in children, so the lowest dose possible must be used. Long-term use may cause mood changes, osteoporosis , sleep irregularities, increased hair growth, cataracts , increased eye pressures (risk for glaucoma ), roundness of the face, or thinning skin, intestinal bleeding, and increase the risk of pneumonia . Suppression of internal corticosteroid production can occur with long-term use. Therefore, if taken for several weeks, dose adjustments should be under a physician's direction. Call your doctor if you experience any of the following:

Pentobarbital has been used or considered as a substitute for other drugs traditionally used for capital punishment in the United States when they are in short supply. [14] Such use however is illegal under Danish law, and when this was discovered, after public outcry in Danish media, Lundbeck, the owner of the drug, stopped selling it to US states that impose the death penalty . US distributors of the drug are forbidden by the owner to sell it to any customers, such as several state authorities, that practice or participate in executions of humans. [15]

Administration advice :
-The IV formulation should be diluted prior to use and the infusion rate should not exceed 60 mg/min in adults.
-If given IM, limit the volume to 5 mL per site. Injections should be administered deeply into large muscles.

Storage requirements :
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques :
-The manufacturer product information should be consulted.

General :
-If discontinuation is necessary, this drug should be withdrawn slowly to prevent seizures or status epilepticus.
-Dosing should be based on a patient's age, weight, and condition.
-Anticonvulsant activity is believed to be present at sub-hypnotic doses.

Monitoring :
-Blood pressure, respiration, and cardiac function during IV administration or IM (at hypnotic doses).
-Hematopoietic, renal and hepatic function periodically, especially during long-term therapy.
-Bone mineral density, especially during prolonged treatment.

Patient advice :
-Advise patients, and families/caregivers to monitor and report signs/symptoms of suicidality, and/or unusual behavior immediately to their healthcare provider (., agitation, irritability, anxiety, panic attacks, insomnia, hostility, aggressiveness, impulsivity, akathisia, hypomania/mania).
-Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or a motor vehicle, until they are reasonably certain that this drug does not adversely affect them.
-Patients should be told to avoid consuming alcohol while taking this drug.
-Instruct patients to immediately report any signs/symptoms of Stevens-Johnson syndrome, toxic epidermal necrolysis, hematological disease, or hypersensitivity reactions.
-Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Oral to iv phenobarbital conversion

oral to iv phenobarbital conversion


oral to iv phenobarbital conversionoral to iv phenobarbital conversionoral to iv phenobarbital conversionoral to iv phenobarbital conversionoral to iv phenobarbital conversion